Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tezepelumab in Japanese Adults and Adolescents With Inadequately Controlled Severe Asthma (NOZOMI)

NCT04048343 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04048343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04048343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tezepelumab in Japanese Adults and Adolescents With Inadequately Controlled Severe Asthma (NOZOMI)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 10, 2019
Completion date
March 18, 2021
Enrollment
65 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

severe asthma